Radiolabeling and brain penetration of [ 11 C]VU0071063, a ligand of type 1 sulfonylurea receptors (SUR1) for PET imaging

Author(s):  
Fabien Caillé ◽  
Wadad Saba ◽  
Sébastien Goutal ◽  
Louise Breuil ◽  
Bertrand Kuhnast ◽  
...  
Amino Acids ◽  
2015 ◽  
Vol 47 (7) ◽  
pp. 1409-1419 ◽  
Author(s):  
Xinhui Su ◽  
Kai Cheng ◽  
Yang Liu ◽  
Xiang Hu ◽  
Shuxian Meng ◽  
...  

2012 ◽  
Vol 39 (8) ◽  
pp. 1232-1235 ◽  
Author(s):  
Akihiro Noda ◽  
Hiroshi Fushiki ◽  
Yoshihiro Murakami ◽  
Hiroshi Sasaki ◽  
Sosuke Miyoshi ◽  
...  

2016 ◽  
Vol 175 (4) ◽  
pp. 335-344 ◽  
Author(s):  
Lori Képénékian ◽  
Thomas Mognetti ◽  
Jean-Christophe Lifante ◽  
Anne-Laure Giraudet ◽  
Claire Houzard ◽  
...  

Objective Pheochromocytoma (PHEO) may occur in 0.1–5.7% of patients presenting with a neurofibromatosis type 1 (NF1). Current recommendations are to explore only symptomatic patients. The objective of the study is to evaluate the prevalence and the interest of a systematic PHEO screening in this population. Design A prospective study in a French tertiary center including consecutive NF1 patients older than 18 years. Methods A systematic screening combining abdominal imaging and urinary fractionated metanephrines was proposed. In case of positivity of one or both exams, 123I-metaiodobenzylguanidine scintigraphy or [18F]-fluoro-dihydroxyphenylalanine PET imaging was performed. The diagnosis of secreting PHEO was retained in case of elevated urinary metanephrines associated with positive scintigraphy and non-secreting PHEO when urinary metanephrines were normal with a positive scintigraphy. Results Between January 2014 and August 2015, 234 patients were included and 156 patients (66.7%) completed both exams. In these 156 patients, 12 PHEOs were diagnosed, representing a prevalence of 7.7%. Of these, six PHEOs were secreting, with only two symptomatic patients. The tumor size of these PHEOs were bigger than that of non-secreting PHEO (25.2 ± 6.6 vs 14 ± 6.9 mm, P = 0.0165). One lesion was bilateral. Mean metanephrine and normetanephrine levels were 3.2 ± 2.6N and 2.8 ± 1N respectively. Three patients underwent surgery. The six patients with non-secreting PHEO were asymptomatic. One of them had bilateral lesion and one underwent surgery. Conclusions PHEO in NF1, whether or not secreting, are mostly asymptomatic. The current strategy to explore only symptomatic patients leads to an underestimation of prevalence with the risks inherent to the existence of an unrecognized PHEO.


2019 ◽  
Vol 61 (4) ◽  
pp. 570-576 ◽  
Author(s):  
Jason Bini ◽  
Elizabeth Sanchez-Rangel ◽  
Jean-Dominique Gallezot ◽  
Mika Naganawa ◽  
Nabeel Nabulsi ◽  
...  

2013 ◽  
Vol 41 (2) ◽  
pp. 308-321 ◽  
Author(s):  
Cindy Casteels ◽  
Nathalie Gérard ◽  
Kris van Kuyck ◽  
Lies Pottel ◽  
Bart Nuttin ◽  
...  

2013 ◽  
Vol 3 (1) ◽  
pp. 59 ◽  
Author(s):  
Kimy M Emonds ◽  
Michel Koole ◽  
Cindy Casteels ◽  
Laura Van den Bergh ◽  
Guy M Bormans ◽  
...  

2010 ◽  
Vol 117 (2-3) ◽  
pp. 170 ◽  
Author(s):  
Jenny Ceccarini ◽  
Marc De Hert ◽  
Ruud van Winkel ◽  
Dagmar Koethe ◽  
Guy Bormans ◽  
...  

2009 ◽  
Vol 48 (03) ◽  
pp. 110-112 ◽  
Author(s):  
H. Petersen ◽  
C. Manniche ◽  
P. F. Høilund-Carlsen ◽  
H. B. Albert

SummaryThe aim of this study was via PET imaging to reveal if any highly metabolic processes were occurring in Modic changes type 1 and/or in the adjacent discs. Modic changes (MC) are signal changes in the vertebral endplate and body visualised by magnetic resonance imaging (MRI). MC are strongly associated with low back pain (LBP). MC type 1 appear to be inflammation on MRI, and histological and biochemical findings make it highly likely that an inflammation is present. Though MC is painful no known treatment is available, and it is unknown which entities affect the progress or regress of MC. The changes observed on MRI are slow and take months to develop, but faster changes in the metabolism might provide a platform for monitoring patients. Patients, methods: Patients from The Back Centre Funen, with low back pain in the area of L1 to S1, MC type 1 in L1 to L5, and a previous herniated lumbar disc. All patients had a PET scan using FDG (18F-fluorodeoxyglucose) as tracer. Results: Included in the study were 11 patients, 4 women and 7 men, mean age 48.1 year (range 20–65). All MC were situated in the vertebrae both above and below the previously herniated disc/discs. Ten patients had MC at 1 level, and 1 had MC at 2 levels. The affected levels were 1 at L2/L3, 6 at L4 /L5, and 5 at L5/S1. All had a previous disc herniation and MC larger than 4 mm in diameter. Technically satisfactory PET scans were obtained. However, PET imaging showed no increases in metabolism in any vertebra or disc of any patient. Conclusion: Modic type 1 changes do not reveal themselves by showing increased metabolism with ordinary FDG PET imaging. PET tracers illuminating inflammation are being developed and hopefully may become more successful.


Sign in / Sign up

Export Citation Format

Share Document